PATENT CLAIM ANALYSIS

Application Number: 15768388
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "300000"]

Abstract:
The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Claim (Index 14):
The method according to  claim 13 , wherein said disorders associated with cellular necroptosis are trauma in brain, hepatitis, alcoholic and non-alcoholic steatohepatitis, acute pancreatitis and acute tubular necrosis, heart or kidney transplantation, atherosclerosis, bone marrow failure, viral infection, Crohn's and ulcerative colitis, terminal ileitis, chronic obstructive pulmonary disease or ischemia reperfusion injury.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 91.0
- Lexical Diversity: 2.21429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15768395', '12086792', '15100967', '11998817', '14703004']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7834168972372713
- 35 USC 102 Novelty (BERT): 0.6405502821661729
- Combined Prediction Score: 0.7691302357301615
- Mean Citation Score: 388.673318
- Max Citation Score: 647.97546
- Similarity Product: 553.7176218622542

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test